WILMINGTON, DE - Enovis (NYSE: ENOV), a prominent medical technology company with a market capitalization of $2.54 billion, has announced the appointment of Davide Visentin as the new President of ...
Enovis (NYSE: ENOV) announced today that it appointed Davide Visentin as the new president of its International Surgical ...
Chicago, IL – January 24, 2025 – Today, Zacks Equity Research Equity are Enovis ENOV, Omnicell OMCL and Phreesia PHR. Link: ...
WILMINGTON, DE — Enovis™ Corporation (NYSE: ENOV), a leading player in the healthcare industry, announced this week that top executives from their team will present at the esteemed Canaccord ...
$40,000 of ENOVIS lobbying was just disclosed, from Q4 of 2024, in a new Lobbying Disclosure Act filing. This included lobbying on issues like: "Medicare DME Competitive Bidding reforms and ...
Wilmington, DE, Jan. 17, 2025 (GLOBE NEWSWIRE) -- Enovisâ„¢, a global medical technology innovator headquartered in the United States, announced recently that Davide Visentin will succeed Dr ...
Oak Thistle LLC acquired a new position in shares of Enovis Co. (NYSE:ENOV – Free Report) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission ...
Enovis has named Davide Visentin as its new president of the international surgical business, according to a Jan. 17 report from Mass Device. Mr. Visentin will succeed Benjamin Reinmann, MD, beginning ...
On Monday, Enovis Corp (ENOV) stock saw a modest uptick, ending the day at $45.35 which represents a slight increase of $0.58 or 1.30% from the prior close of $44.77. The stock opened at $44.43 and ...
In a report released yesterday, Vik Chopra from Wells Fargo reiterated a Buy rating on Enovis (ENOV – Research Report), with a price target of ...
Check the time stamp on this data. Updated AI-Generated Signals for Enovis Corporation (ENOV) available here: ENOV. Type a ...
Wilmington, DE, Jan. 17, 2025 (GLOBE NEWSWIRE) -- Enovisâ„¢, a global medical technology innovator headquartered in the United States, announced recently that Davide Visentin will succeed Dr. Benjamin ...